Prix
Questions fréquentes
Quelle est la capitalisation boursière de AC Immune ?
Quel est le bénéfice par action (BPA) de AC Immune ?
Quelles sont les évaluations des analystes et le prix cible de l'action AC Immune ?
Quel est le chiffre d'affaires de AC Immune sur les douze derniers mois ?
Quel est l'EBITDA de AC Immune ?
Quel est le flux de trésorerie disponible de AC Immune ?
Quel est le bêta à 5 ans de l'action AC Immune ?
Combien d'employés compte AC Immune, et à quel secteur d'activité appartient-elle ?
Quel est le flottant des actions de AC Immune ?
Finances
Capitalisation boursière
325,51 M $USbêta sur 5 ans
1,24BPA (TTM)
-0,461 $USFree Float
77,34 MRecettes (TTM)
46,22 M $USEBITDA (TTM)
-39,61 M $USCash-flow disponible (TTM)
48,58 M $USCotation
Notes des analystes
L'objectif de prix est de 10,46 $US et l'action est analysée par 4 analystes.
Acheter
4
Hold
0
Vendre
0
Informations
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
133
Biotechnology & Drugs
Soins de santé
Identifiant
ISIN
Ticker primaire